NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

GlobeNewswire

Image Credit: GlobeNewswire

Please find more details at GlobeNewswire

Summary

Transaction expected to approximately triple NEXGELs annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing

Source: GlobeNewswire

Read More

(0)

Exclusive AI-Powered News Insights (For Members only)

Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!